CagriSema vs Palmitoyl Tripeptide-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Palmitoyl Tripeptide-1 |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Very well-tolerated. Suitable for most skin types including sensitive skin. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to Palmitoyl Tripeptide-1:
Detailed Analysis
Commonalities
CagriSema and Palmitoyl Tripeptide-1 are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose Palmitoyl Tripeptide-1 for Anti-Aging & Longevity, Skin Health & Aesthetics.
Ready to Learn More?
Looking for trusted sources?